Severe Hypertriglyceridemia Clinical Trial
Official title:
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal Function
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01208961 -
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
|
Phase 2 | |
Completed |
NCT04541186 -
Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia
|
Phase 2 | |
Active, not recruiting |
NCT05079919 -
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT02189252 -
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
|
Phase 1 | |
Active, not recruiting |
NCT01229566 -
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT03011450 -
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT05355402 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT04720534 -
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
|
Phase 2 | |
Recruiting |
NCT06347016 -
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
|
Phase 3 | |
Recruiting |
NCT06347003 -
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
|
Phase 3 | |
Withdrawn |
NCT04662528 -
Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL
|
Phase 3 | |
Recruiting |
NCT05852431 -
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT01242527 -
Epanova® for Lowering Very High Triglycerides
|
Phase 2/Phase 3 | |
Completed |
NCT02944383 -
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
|
Phase 2 | |
Recruiting |
NCT05681351 -
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
|
Phase 3 | |
Recruiting |
NCT05552326 -
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
|
Phase 3 | |
Withdrawn |
NCT01997268 -
The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)
|
Phase 3 |